711 Ex vivo preclinical study of colon cancer using Opto-magnetic imaging spectroscopy and dual speed spinner magnetometer

2015 ◽  
Vol 51 ◽  
pp. S130-S131 ◽  
Author(s):  
A. Dragicevic ◽  
Z. Krivokapic ◽  
I. Dimitrijevic ◽  
V. Markovic ◽  
L. Matija ◽  
...  
2014 ◽  
Vol 5 (1) ◽  
Author(s):  
Aleksandra Dragičević ◽  
Zoran Krivokapić ◽  
Velimir Marković ◽  
Gorana Nikolić ◽  
Lidija Matija

According to the World Health Organization cancer is the leading cause of death worldwide and on the third place is the most common and dangerous colorectal cancer with the rate of 17.3/100,000 people. Therefore, it is necessary to find effective solutions to improve the quality and speed of diagnostic tools so that they can respond to the challenges of prevention strategies which are an integral part of the rapid diagnosis of a large number of patients. The objectives of the research conducted in this study (in vitro) are: (1) examining the possibilities of application of opto-magnetic imaging spectroscopy for characterization between different types of colon cancer, stained and non-stained plates, (2) method validation, (3) parameters determination for research in in vivo conditions, and (4) application in clinical trial to increase the efficiency and give more reliable diagnosis. In this paper we present Opto-magnetic imaging spectroscopy (OMIS) as a novel optical method for differentiation of different types of colon cancer, significant similarity between stained and non-stained plates based on light-tissue interaction. Results have showed that OMIS can make a difference between colorectal carcinoma and other types of colon cancer, as well as prove that plates staining can be avoided.


2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Elodie A. Pérès ◽  
Jérôme Toutain ◽  
Louis-Paul Paty ◽  
Didier Divoux ◽  
Méziane Ibazizène ◽  
...  

Abstract Background Diacetyl-bis(N4-methylthiosemicarbazone), labeled with 64Cu (64Cu-ATSM) has been suggested as a promising tracer for imaging hypoxia. However, various controversial studies highlighted potential pitfalls that may disable its use as a selective hypoxic marker. They also highlighted that the results may be tumor location dependent. Here, we first analyzed uptake of Cu-ATSM and its less lipophilic counterpart Cu-Cl2 in the tumor over time in an orthotopic glioblastoma model. An in vitro study was also conducted to investigate the hypoxia-dependent copper uptake in tumor cells. We then further performed a comprehensive ex vivo study to compare 64Cu uptake to hypoxic markers, specific cellular reactions, and also transporter expression. Methods μPET was performed 14 days (18F-FMISO), 15 days (64Cu-ATSM and 64Cu-Cl2), and 16 days (64Cu-ATSM and 64Cu-Cl2) after C6 cell inoculation. Thereafter, the brains were withdrawn for further autoradiography and immunohistochemistry. C6 cells were also grown in hypoxic workstation to analyze cellular uptake of Cu complexes in different oxygen levels. Results In vivo results showed that Cu-ASTM and Cu-Cl2 accumulated in hypoxic areas of the tumors. Cu-ATSM also stained, to a lesser extent, non-hypoxic regions, such as regions of astrogliosis, with high expression of copper transporters and in particular DMT-1 and CTR1, and also characterized by the expression of elevated astrogliosis. In vitro results show that 64Cu-ATSM showed an increase in the uptake only in severe hypoxia at 0.5 and 0.2% of oxygen while for 64Cu-Cl2, the cell retention was significantly increased at 5% and 1% of oxygen with no significant rise at lower oxygen percentages. Conclusion In the present study, we show that Cu-complexes undoubtedly accumulate in hypoxic areas of the tumors. This uptake may be the reflection of a direct dependency to a redox metabolism and also a reflection of hypoxic-induced overexpression of transporters. We also show that Cu-ATSM also stained non-hypoxic regions such as astrogliosis.


Cancers ◽  
2021 ◽  
Vol 13 (20) ◽  
pp. 5159
Author(s):  
Janani Panneerselvam ◽  
Venkateshwar Madka ◽  
Rajani Rai ◽  
Katherine T. Morris ◽  
Courtney W. Houchen ◽  
...  

Obesity-associated chronic inflammation predisposes colon cancer risk development. Interleukin-23 (IL-23) is a potential inflammatory mediator linking obesity to chronic colonic inflammation, altered gut microbiome, and colon carcinogenesis. We aimed to elucidate the role of pro-inflammatory eicosanoids and gut bacterial toxins in priming dendritic cells and macrophages for IL-23 secretion to promote colon tumor progression. To investigate the association of IL-23 with obesity and colon tumorigenesis, we utilized TCGA data set and colonic tumors from humans and preclinical models. To understand IL-23 production by inflammatory mediators and gut microbial toxins, we performed several in vitro mechanistic studies to mimic the tumor microenvironment. Colonic tumors were utilized to perform the ex vivo experiments. Our findings showed that IL-23 is elevated in obese individuals, colonic tumors and correlated with reduced disease-free survival. In vitro studies showed that IL-23 treatment increased the colon tumor cell self-renewal, migration, and invasion while disrupting epithelial barrier permeability. Co-culture experiments of educated dendritic cells/macrophages with colon cancer cells significantly increased the tumor aggression by increasing the secretory levels of IL-23, and these observations are further supported by ex vivo rat colonic tumor organotypic experiments. Our results demonstrate gut microbe toxins and eicosanoids facilitate IL-23 production, which plays an important role in obesity-associated colonic tumor progression. This newly identified nexus represents a potential target for the prevention and treatment of obesity-associated colon cancer.


2018 ◽  
Vol 39 (3) ◽  
pp. 367-380 ◽  
Author(s):  
Aleksandra Dragicevic ◽  
Lidija Matija ◽  
Zoran Krivokapic ◽  
Ivan Dimitrijevic ◽  
Marko Baros ◽  
...  

2018 ◽  
Vol 400 (1) ◽  
pp. 111-122 ◽  
Author(s):  
Christin Schneider ◽  
Stephanie Arndt ◽  
Julia L. Zimmermann ◽  
Yangfang Li ◽  
Sigrid Karrer ◽  
...  

AbstractPlasma oncology is a relatively new field of research. Recent developments have indicated that cold atmospheric plasma (CAP) technology is an interesting new therapeutic approach to cancer treatment. In this study, p53 wildtype (LoVo) and human p53 mutated (HT29 and SW480) colorectal cancer cells were treated with the miniFlatPlaSter – a device particularly developed for the treatment of tumor cells – that uses the Surface Micro Discharge (SMD) technology for plasma production in air. The present study analyzed the effects of plasma on colorectal cancer cellsin vitroand on normal colon tissueex vivo. Plasma treatment had strong effects on colon cancer cells, such as inhibition of cell proliferation, induction of cell death and modulation of p21 expression. In contrast, CAP treatment of murine colon tissueex vivofor up to 2 min did not show any toxic effect on normal colon cells compared to H2O2positive control. In summary, these results suggest that the miniFlatPlaSter plasma device is able to kill colorectal cancer cells independent of their p53 mutation status. Thus, this device presents a promising new approach in colon cancer therapy.


2020 ◽  
Vol 41 (9) ◽  
pp. 1219-1228
Author(s):  
Seçil Demirkol Canlı ◽  
Esin Gülce Seza ◽  
Ilir Sheraj ◽  
Ismail Gömçeli ◽  
Nesrin Turhan ◽  
...  

Abstract AKR1B1 and AKR1B10, members of the aldo-keto reductase family of enzymes that participate in the polyol pathway of aldehyde metabolism, are aberrantly expressed in colon cancer. We previously showed that high expression of AKR1B1 (AKR1B1HIGH) was associated with enhanced motility, inflammation and poor clinical outcome in colon cancer patients. Using publicly available datasets and ex vivo gene expression analysis (n = 51, Ankara cohort), we have validated our previous in silico finding that AKR1B1HIGH was associated with worse overall survival (OS) compared with patients with low expression of AKR1B1 (AKR1B1LOW) samples. A combined signature of AKR1B1HIGH and AKR1B10LOW was significantly associated with worse recurrence-free survival (RFS) in microsatellite stable (MSS) patients and in patients with distal colon tumors as well as a higher mesenchymal signature when compared with AKR1B1LOW/AKR1B10HIGH tumors. When the patients were stratified according to consensus molecular subtypes (CMS), AKR1B1HIGH/AKR1B10LOW samples were primarily classified as CMS4 with predominantly mesenchymal characteristics while AKR1B1LOW/AKR1B10HIGH samples were primarily classified as CMS3 which is associated with metabolic deregulation. Reverse Phase Protein Array carried out using protein samples from the Ankara cohort indicated that AKR1B1HIGH/AKR1B10LOW tumors showed aberrant activation of metabolic pathways. Western blot analysis of AKR1B1HIGH/AKR1B10LOW colon cancer cell lines also suggested aberrant activation of nutrient-sensing pathways. Collectively, our data suggest that the AKR1B1HIGH/AKR1B10LOW signature may be predictive of poor prognosis, aberrant activation of metabolic pathways, and can be considered as a novel biomarker for colon cancer prognostication.


2011 ◽  
Vol 13 (11) ◽  
pp. 1249-1255 ◽  
Author(s):  
E. B. Rivet ◽  
M. G. Mutch ◽  
J. H. Ritter ◽  
A. A. Khan ◽  
J. S. Lewis ◽  
...  

PROTEOMICS ◽  
2009 ◽  
Vol 9 (13) ◽  
pp. 3535-3548 ◽  
Author(s):  
Farzaneh Pirnia ◽  
Michael Pawlak ◽  
Gerhard G. Thallinger ◽  
Berthold Gierke ◽  
Markus F. Templin ◽  
...  

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. 4063-4063
Author(s):  
Robert Alan Nagourney ◽  
Steven Scott Evans ◽  
Paula J Bernard ◽  
Adam Nagourney ◽  
Peter Tran ◽  
...  

4063 Background: Numerous studies suggest benefit for heated intra-peritoneal chemotherapy (HIPEC) in colon cancer but the Prodige 7 trial in 265 colon cancer patients randomized to HIPEC or observation after neo-adjuvant chemotherapy (NACT) didn't confirm benefit with median OS of 41.7 vs. 41.2 mos. (p = 0.99) (Proc. ASCO, 2018). One concern is that prior drug exposure selects for drug resistance blunting HIPEC effect. To test the hypothesis we examined the impact of prior chemotherapy on drug resistance in human tumor organoids isolated from colon cancer patients. Methods: Data query identified 111 colorectal cancers (87 colon & 24 rectal) tested for Oxaliplatin sensitivity by ex vivo analysis of programmed cell death (EVA/PCD), a primary culture platform that examines drug induced cell death (apoptotic & non-apoptotic) by morphology, metabolism & histology. Five-point dose response curves interpolated to provide lethal concentration 50% (LC50) were compared by Z score to distribute Oxaliplatin LC50 values around the mean using standard deviation units as the metric of sensitivity or resistance. Of 87 colon 54(62%) were untreated and 33 (38%) treated with 21/33 (64%) having received FOLFOX. To approximate Prodige 7, treated patients were separated by having received FOLFOX < 2 > months before EVA/PCD analysis and also compared Mitomycin (14 vs 41), Irinotecan (18 vs 47) & 5-FU (19 vs. 52) activity to assess cross-resistance. Results: Compared to chemo-naïve, FOLFOX-treated patients were significantly more resistant to Oxaliplatin (P < 0.01) with the degree of resistance increasing significantly for patients who received treatment < 2 months prior to EVA/PCD compared to those with chemotherapy > 2 months prior to EVA/PCD (P < 0.01). Activity for Mitomycin & Irinotecan was not significantly different for chemo-naïve vs. treated patients, but 5 FU was more resistant (P = 0.048) in previously treated. Conclusions: The failure of Prodige 7 to improve survival with HIPEC following NACT may reflect diminished Oxaliplatin activity in patients whose residual disease has been selected for Oxaliplatin & 5FU resistance. Resistance was not observed for Mitomycin or Irinotecan. This suggests that those using HIPEC may i) examine other classes of drugs or drug combinations for IP administration ii) improve the selection of candidates for HIPEC administration or iii) consider HIPEC administration earlier in the course of therapy when chemotherapy-induced drug resistance may be less evident.


Sign in / Sign up

Export Citation Format

Share Document